News und Analysen
QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and
Chemed Corporation to Present at the 2021 RBC Capital Markets Global Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at approximately 10:20
Merritt Hawkins Survey: New Physicians Getting Fewer Recruiting Offers
Physicians completing their training are getting fewer recruiting offers than in the past, most likely due to Covid-19, a new survey suggests. The survey also indicates that female physicians
AMN Healthcare Announces First Quarter 2021 Results
AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2021 financial
93rd Vifor Pharma Group Annual General Meeting
Regulatory News:
At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19
93. Generalversammlung der Vifor Pharma Gruppe
Regulatory News:
An der 93. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt. Angesichts der anhaltenden
Xencor Reports First Quarter 2021 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
Premier Inc. to Participate in BofA Securities Virtual 2021 Healthcare Conference on May 11, 2021
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the BofA Securities
Acadia Healthcare to Participate in the BofA Securities 2021 Healthcare Conference and the 2021 RBC Capital Markets Global Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two upcoming virtual healthcare conferences.
On Thursday, May 13, 2021, the Company will
Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced first-quarter 2021 financial results. The Company updated its full-year 2021 net sales guidance and its adjusted EBITDA guidance to
ICON plc to Present at the BofA Securities 2021 Virtual Healthcare Conference and the UBS Virtual Global Healthcare Conference
ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
Chemed Corporation to Present at the BofA Securities 2021 Virtual Health Care Conference
Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021, at 12:30 PM (ET).
The presentation will be
Charles River Laboratories Announces First-Quarter 2021 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2021. For the quarter, revenue was $824.6 million, an increase of 16.6% from $707.1
Premier, Inc. Reports Fiscal-Year 2021 Third-Quarter Results and Raises Fiscal Year 2021 Guidance
Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year (FY) 2021 third quarter ended March 31, 2021 and raised its fiscal 2021 financial guidance.
"I am excited to take
QIAGEN übertrifft Prognose im ersten Quartal 2021, bekräftigt Ausblick bezüglich Umsatzwachstum und Profitabilität für das Gesamtjahr 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die starken Ergebnisse der operativen Tätigkeit für das erste Quartal 2021 bekannt. Das Unternehmen hat seine Ziele für den
QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the first quarter of 2021, exceeding the goals for net sales and adjusted earnings per share.
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21)
Acadia Healthcare Reports First Quarter 2021 Results and Increases 2021 Guidance
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2021.
First Quarter 2021 Results
The Company reported revenue of $551.2
QIAGEN kündigt EZ2-Connect-Instrumentenlinie für die automatisierte Probenverarbeitung in der Forschung, Forensik und Diagnostik an
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Einführung der EZ2-Connect-Produktlinie angekündigt. Mit seiner neuen Plattform hebt das Unternehmen die Probenverarbeitung auf
QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the upcoming launch of the EZ2 Connect product line, a next-level automated sample-processing platform whose simplicity
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial strength despite changes in patterns of care in some regions driven
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/
Vifor Pharma and Angion Biomedica Corp. (NASDAQ
Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today
Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today